EUVIMED · CrossrefJournal
Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish
ISSN 2283-5733 · Aboutscience Srl
Latest articles
AIFA monitoring registries as a strategic tool in the Italian HTA framework: evolution and policy implications
Implementing the EU HTA Regulation in Italy: a multi-stakeholder perspective from the Mogliano Veneto Working Group
The role of osimertinib in the therapeutic pathway of EGFR-mutated NSCLC: results from an Italian Delphi Consensus
How reliable are ICER’s results published in current pharmacoeconomic literature? The controversial issue of price confidentiality
Economic burden of disease of uncontrolled acromegalic patients: the acromegaly Italian collaborative study group
Burden of disease, healthcare pathways and costs of cardiovascular high-risk patients with type 2 diabetes: a real world analysis
Assessing social and economic impact of subcutaneous mAbs in oncology
A comparative examination of healthcare use related to hearing impairment in Europe
Analisi di impatto sul budget di differenti analoghi ad azione rapida dell’insulina in Italia
Analisi di Budget Impact su modelli di acquisto e gestione degli ausili per l’incontinenza urinaria a confronto
Analisi di budget impact del biosimilare di etanercept: lo scenario italiano
Patients’ Associations and HTA for medicines: actual and future role in Italy
The economic impact of the correct insulin injection technique associated with the use of 4 mm 32G needles in the treatment of patients with type 2 diabetes
The hospitalization burden of influenza: just the tip of the iceberg?
Epidemiology and economic impact of moderate and severe neurotrophic keratopathy in Italy
Alirocumab in the management of primary hypercholesterolaemia or mixed dyslipidaemia: A budget impact analysis – Italian perspective
Corrigendum
Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives
Cost-description and multiple imputation of missing values: the SATisfaction and adherence to COPD treatment (SAT) study
Costo-Efficacia di cabozantinib nel trattamento di seconda linea del tumore a cellule renali metastatico (mRCC) in Italia
Mean cost per number needed to treat of baricitinib versus adalimumab in the treatment of rheumatoid arthritis in Italy
Accesso precoce al mercato: dalle approvazioni condizionate di EMA agli accordi negoziali particolari di AIFA
Tempi di accesso ai farmaci in Italia nel periodo 2015-2017: Analisi delle tempistiche di valutazione dell’Agenzia Italiana del Farmaco
I costi dei pazienti con patologie infiammatorie dell’intestino (Malattia di Crohn e colite ulcerosa). Studio real world in Italia
Il trattamento con farmaci intravitreali anti-VEGF in pazienti naïve in Italia
Evaluación del impacto presupuestario del servicio integral de asistencia domiciliaria nutricional
Budget impact model of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease in Italy based on the FLAME study
A budget impact analysis of a clinical medication review of patients in an Irish university teaching hospital
Cost per responder for ixekizumab and other biologic drugs approved for the treatment of moderate-to-severe plaque psoriasis in Italy
Cost per response/remission in biologics available in Italy for the treatment of TNF-α inhibitors-naïve patients with ulcerative colitis
EUVIMED